ArticleMedicine2026
Development and validation of a ferroptosis and metabolic reprogramming gene signature for risk stratification in bladder urothelial carcinoma: A retrospective multicohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Bladder urothelial carcinoma (BLCA) is clinically and molecularly heterogeneous, and conventional clinicopathologic factors do not fully reflect the biological variation associated with survival. We aimed to develop and externally evaluate a prognostic signature based on genes related to both ferroptosis and metabolic reprogramming and to examine its clinical and biological associations. The Cancer Genome Atlas (TCGA)-BLCA transcriptomic and clinical data were used for candidate-gene identification and model development. A 10-gene least absolute shrinkage and selection operator Cox signature was evaluated by complete-pipeline bootstrap validation. After platform harmonization, the same coefficients and TCGA-derived cutoff were applied to GSE13507 and GSE48075. Clinical adjustment, stage-specific analyses, immune analyses accounting for the IFNG score contribution, tumor purity, and molecular subtype, exploratory drug-response prediction, and expression analysis in 15 paired institutional tumor and adjacent tissues were performed. The signature comprised JUN, IFNG, CAV1, SREBF1, G6PD, TFRC, SCD, ZEB1, SLC7A11, and WWTR1. In TCGA-BLCA (401 patients; 176 deaths), the high-risk group had poorer overall survival (hazard ratio [HR] = 2.313; 95% confidence interval = 1.697-3.154; P < .001). The fixed TCGA cutoff also identified high-risk groups in GSE13507 (165 patients; 69 deaths; HR = 2.202; P = .0010) and GSE48075 (73 patients; 45 deaths; HR = 2.476; P = .0082). The 10-gene RiskScore yielded 1-, 3-, and 5-year areas under the curve of 0.644, 0.657, and 0.668 in TCGA-BLCA; the corresponding values ranged from 0.583 to 0.696 in the external cohorts. RiskScore remained associated with survival after adjustment for age, sex, and stage in TCGA (HR per standard-deviation increase, 1.573; P < .001). In the paired institutional cohort, 5 genes differed between tumor and adjacent tissues at a false discovery rate below 0.05, and 9 of 10 genes showed expression directions concordant with TCGA. Enrichment analyses highlighted oxidative-stress and metabolic pathways; several immune and checkpoint associations remained after sensitivity analyses, and exploratory modeling identified risk-group differences in predicted drug sensitivity. The 10-gene signature consistently stratified overall survival across TCGA-BLCA and 2 independent Gene Expression Omnibus cohorts. Its associations with clinical outcome, paired-tissue expression, and immune features support further investigation of ferroptosis-related metabolic heterogeneity in BLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.